April 2018 - FRMC

Issue 4
April 2018


Dean Celia

A case in California involving an Aetna medical director who denied treatment without looking at patient records recently caused a stir in the media. We spoke with our experts to review best practices, how to involve nurses and specialists in health care decisions, and whether more transparency is in order. | Read More

Paul Nicolaus

As the Trump Administration takes measures to broaden the moral and religious rights of health care professionals, critics say these moves may exacerbate existing social determinants of health among LGBT patients. | Read More

Mary Beth Nierengarten

A number of states have recently launched a range of attacks on the ACA, from offering plans that don’t meet its requirements to challenging its constitutionality. | Read More


A featured poster session at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting detailed the results of a study comparing the efficacy and tolerability of PARP inhibitors as maintenance treatment in BRCA-mutated platinum-sensitive relapsed ovarian cancer. | Read More
Joyce F Liu, MD, MPH, recently discussed the current and future role of PARP inhibitors for the treatment of ovarian cancer at the Society of Gynecologic Oncology’s 2018 Annual Meeting. | Read More
The American Society of Clinical Oncology’s (ASCO) Patient-Centered Oncology Payment (PCOP) model helps achieve costs savings in ovarian cancer when hospitalizations are reduced during the active treatment period, according to a study presented at the Society of Gynecologic Oncology’s (SGO) 2018 Annual Meeting. | Read More
Recent research presented at the ACC 2018 Scientific Session found that urgent or emergent transcatheter aortic valve replacement (TAVR) has acceptable outcomes when compared with elective TAVR.  | Read More